Attend virtual education event for gynecologic cancer care
Join Andrea Hardy, RN, BSN, Providence gynecologic oncology nurse care coordinator, on March 9 for Coping with Chemotherapy. This is a free, virtual educational event for gynecologic cancer patients and their caregivers presented by the Ovarian Cancer Alliance of Oregon & SW Washington in collaboration with Providence Cancer Institute of Oregon.
Andrea will help empower patients to take an active role in their own health care by helping them understand chemotherapy and its side effects, both physically and emotionally.
Topics will include:
- Taking an active role in your care
- Understanding chemotherapy
- Most common types of chemotherapy, including immunotherapy and oral PARP inhibitors
- Understanding and managing the side effects of chemotherapy
- Communicating with your health care team
Event details
Wednesday, March 9, 2022
5:00 p.m. - 6:15 p.m. PT
About the presenter
Andrea Hardy, RN, BSN, is a Gynecologic Oncology Nurse Care Coordinator at Providence Cancer Institute of Oregon. She cares for patients with gynecologic cancer throughout their diagnosis, treatment, and survivorship. Among her various nursing services, Andrea provides patient education for symptom management over the course of treatments, starting with chemotherapy. This support helps to ease the journey into the unknown and empowers patients to participate in their own health care.
About the Providence Gynecologic Oncology Program
The Providence Gynecologic Cancer Program provides highly specialized care for patients diagnosed with ovarian, cervical, uterine, vaginal, vulvar and other female reproductive tract cancers, as well as pre-cancerous conditions. Patients receive advanced treatments, from robotic surgery to immunotherapy, with the opportunity to participate in clinical trials. To learn more, visit ProvidenceOregon.org/gyncancer.
Related resources
Gynecologic oncology care now available at Providence Cancer Institute
Clinical trial aims to help premenopausal women at risk for ovarian cancer
Phase II study of neoadjuvant combination therapy for ovarian cancer